Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study.
BACKGROUND
Although full costs (including direct and indirect costs) that incurred during the process of chemotherapy administration should be measured, many studies estimate only direct labor and medication costs associated with various chemotherapy delivery systems.


OBJECTIVE
To estimate the total costs for dispensing and administration of fluorouracil when administered with leucovorin, by intravenous infusion or bolus, using a microcosting approach from the perspective of a provider or health system.


METHODS
A time-and-motion study was used to measure the time spent by (1) pharmacy staff in the handling, admixture, and dispensing of fluorouracil and (2) patients in the clinic. The study was performed at The Cancer Institute of New Jersey for an 8-month period. Costs of dispensing and administering fluorouracil were calculated per patient visit on the basis of resources used in the processing of fluorouracil and time spent by pharmacy staff and patient. All costs were standardized to 2005 dollars.


RESULTS
A total of 275 observations were made, and 74 (26.9%) of these were associated with fluorouracil-based chemotherapy. Pharmacy staff spent an average of 11 minutes for bolus fluorouracil with leucovorin infusion (fluorouracil/LCV-IV) and 8 minutes for bolus fluorouracil with bolus leucovorin (fluorouracil/LCV-B). Patients who received fluorouracil/LCV-IV spent an average of 203 minutes in the clinic, whereas patients who received fluorouracil/LCV-B spent 110 minutes. The average cost of administering fluorouracil/LCV-IV was $933, which comprised drug costs ($279), dispensing costs ($189), and administration costs ($465). The average cost of fluorouracil/LCV-B was $474, which comprised drug costs ($65), dispensing costs ($141), and administration costs ($268).


CONCLUSIONS
This is the first study to formally demonstrate the high cost of administering the injectable form of fluorouracil chemotherapy with leucovorin, despite relatively low drug acquisition cost. Therefore, reimbursement rates for fluorouracil should be calculated in such a way that covers all costs, including overhead costs for the department.
Suh
Dong-Churl
DC
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020, USA. dsuh@rci.rutgers.edu
Powers
Christopher A
CA
Barone
Joseph A
JA
Shin
HyunChul
H
Kwon
Jinweon
J
Goodin
Susan
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics*; D016527:Drug Costs; D005472:Fluorouracil / Q000008:administration & dosage / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D002955:Leucovorin / Q000008:administration & dosage; D009515:New Jersey; D010045:Outpatients; D010607:Pharmacy Service, Hospital / Q000191:economics* / Q000458:organization & administration; D013996:Time and Motion Studies
D002955:Leucovorin; D005472:Fluorouracil
N Engl J Med. 2004 Jul 22;351(4):317-9
15269308
Hematol Oncol Clin North Am. 2006 Feb;20(1):119-39
16580560
Clin Ther. 2004 Apr;26(4):579-89
15189755
Breast Cancer Res Treat. 1993;25(2):119-26
8347844
N Engl J Med. 1994 Apr 21;330(16):1136-42
8133857
Cancer Chemother Pharmacol. 2006 Nov;58(5):570-6
16463059
J Nurs Adm. 2000 Mar;30(3):118-25
10725940
Eur J Cancer. 1996;32A Suppl 5:S13-7
8958037
J Manag Care Pharm. 2006 Sep;12(7):570-7
16981802
Pharmacoeconomics. 2003;21(14):1039-51
13129416
Anticancer Drugs. 1997 Aug;8 Suppl 2:S23-6
9376634
Cancer Immunol Immunother. 2006 Nov;55(11):1396-405
16485127
J Clin Oncol. 1998 Jul;16(7):2557-67
9667278
J Clin Oncol. 2004 Jun 1;22(11):2214-32
15169811
World J Gastroenterol. 2006 Jul 14;12(26):4185-90
16830371
Cancer. 1996 Jul 15;78(2):294-9
8674006
Anticancer Drugs. 1996 Aug;7(6):649-54
8913433
Br J Cancer. 2006 Apr 24;94(8):1122-9
16622438
Cancer Invest. 1996;14(2):184-6
8597906
Cancer. 2006 May 1;106(9):1940-9
16532436
Support Care Cancer. 2001 Oct;9(7):545-51
11680835
Pharmacoeconomics. 2000 Apr;17(4):361-70
10947491
Arthritis Care Res. 1997 Oct;10(5):343-51
9362601